StockTipsArenaBeta

BUY Aurobindo Pharma — Swati Hotkar, Nirmal Bang Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

bySwati Hotkar, Nirmal Bang SecuritiesHorizon: 1–3 months18 Aug 2026via NDTV Profit

Entry₹1,600Stated
Target₹1,700
Total upside +6.25% (call closed)
Stop lossNot given
Exit₹1,70031 Aug 2026, 12:08 pm
Target hit+6.25%0.00%upside left
Follow Swati Hotkar for new calls(50% target hit, 18 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 43 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 31 Aug 2026
20 supporting6 neutral8 opposing
Supports the BUY call (20)

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · today

(opens in new tab)

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in

BSE · Company Update·31 Aug · today

(opens in new tab)

7 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·31 Aug · today

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · 1w ago

(opens in new tab)

Aurobindo Pharma US FDA inspection ends with one observation at AuroPeptides facility

NewsCnbc-Tv18·21 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (6)

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 2d ago

(opens in new tab)

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · 1w ago

(opens in new tab)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · 4w ago

(opens in new tab)

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (8)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 2d ago

(opens in new tab)

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · 1w ago

(opens in new tab)

Aurobindo Pharma shares in focus after USFDA closes Raleigh unit inspection with 11 observations

NewsCnbc-Tv18·17 Aug · 2w ago

(opens in new tab)

Aurobindo Pharma shares fall after USFDA issues warning letter to Eugia's Unit 1

NewsCnbc-Tv18·14 Aug · 2w ago

(opens in new tab)

1 other SEBI-registered advisor has an active short-term SELL call on this stock

Advisor consensus · same horizon·6 Aug · 4w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Swati Hotkar, Nirmal Bang Securities

Every call and its outcome